539523 Stock Overview
Alkem Laboratories Limited, a pharmaceutical company, develops, manufactures, and sells pharmaceutical and nutraceutical products in India and internationally.
Alkem Laboratories Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹3,454.25|
|52 Week High||₹4,067.70|
|52 Week Low||₹2,544.25|
|1 Month Change||-0.65%|
|3 Month Change||-6.42%|
|1 Year Change||12.90%|
|3 Year Change||84.66%|
|5 Year Change||103.63%|
|Change since IPO||150.05%|
Recent News & Updates
|539523||IN Pharmaceuticals||IN Market|
Return vs Industry: 539523 exceeded the Indian Pharmaceuticals industry which returned 6.2% over the past year.
Return vs Market: 539523 underperformed the Indian Market which returned 30.7% over the past year.
|539523 Average Weekly Movement||4.0%|
|Pharmaceuticals Industry Average Movement||6.0%|
|Market Average Movement||6.8%|
|10% most volatile stocks in IN Market||10.1%|
|10% least volatile stocks in IN Market||4.1%|
Stable Share Price: 539523 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 539523's weekly volatility (4%) has been stable over the past year.
About the Company
Alkem Laboratories Limited, a pharmaceutical company, develops, manufactures, and sells pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, diabetology, cardiology, gastroenterology, osteoporosis, central nervous system, oncology, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain relief/analgesic, anti-diabetic, and neurology products. It also provides pregnancy detection kits and condoms.
Alkem Laboratories Fundamentals Summary
|539523 fundamental statistics|
Is 539523 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|539523 income statement (TTM)|
|Cost of Revenue||₹40.60b|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Feb 04, 2022
|Earnings per share (EPS)||142.46|
|Net Profit Margin||16.96%|
How did 539523 perform over the long term?See historical performance and comparison
0.9%Current Dividend Yield
Is Alkem Laboratories undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 539523 (₹3454.25) is trading above our estimate of fair value (₹2780.97)
Significantly Below Fair Value: 539523 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 539523 is good value based on its PE Ratio (24.2x) compared to the Indian Pharmaceuticals industry average (25.2x).
PE vs Market: 539523 is poor value based on its PE Ratio (24.2x) compared to the Indian market (22.3x).
Price to Earnings Growth Ratio
PEG Ratio: 539523 is poor value based on its PEG Ratio (1.9x)
Price to Book Ratio
PB vs Industry: 539523 is overvalued based on its PB Ratio (5x) compared to the IN Pharmaceuticals industry average (3.1x).
How is Alkem Laboratories forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 539523's forecast earnings growth (12.7% per year) is above the savings rate (6.7%).
Earnings vs Market: 539523's earnings (12.7% per year) are forecast to grow slower than the Indian market (21.3% per year).
High Growth Earnings: 539523's earnings are forecast to grow, but not significantly.
Revenue vs Market: 539523's revenue (10.5% per year) is forecast to grow slower than the Indian market (13.1% per year).
High Growth Revenue: 539523's revenue (10.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 539523's Return on Equity is forecast to be high in 3 years time (20.1%)
How has Alkem Laboratories performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 539523 has high quality earnings.
Growing Profit Margin: 539523's current net profit margins (17%) are lower than last year (17%).
Past Earnings Growth Analysis
Earnings Trend: 539523's earnings have grown significantly by 20.7% per year over the past 5 years.
Accelerating Growth: 539523's earnings growth over the past year (16.3%) is below its 5-year average (20.7% per year).
Earnings vs Industry: 539523 earnings growth over the past year (16.3%) underperformed the Pharmaceuticals industry 29.7%.
Return on Equity
High ROE: 539523's Return on Equity (20.5%) is considered high.
How is Alkem Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: 539523's short term assets (₹76.9B) exceed its short term liabilities (₹37.1B).
Long Term Liabilities: 539523's short term assets (₹76.9B) exceed its long term liabilities (₹4.3B).
Debt to Equity History and Analysis
Debt Level: 539523 has more cash than its total debt.
Reducing Debt: 539523's debt to equity ratio has increased from 15.5% to 20% over the past 5 years.
Debt Coverage: 539523's debt is well covered by operating cash flow (77.3%).
Interest Coverage: 539523 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Alkem Laboratories's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 539523's dividend (0.87%) is higher than the bottom 25% of dividend payers in the Indian market (0.31%).
High Dividend: 539523's dividend (0.87%) is low compared to the top 25% of dividend payers in the Indian market (1.37%).
Stability and Growth of Payments
Stable Dividend: 539523 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 539523's dividend payments have increased, but the company has only paid a dividend for 6 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (3.5%), 539523's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 539523's dividends in 3 years are forecast to be well covered by earnings (19.6% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sandeep Singh (39 yo)
Mr. Sandeep Derjit Singh has been Managing Director of Alkem Laboratories Limited since October 17, 2017. Mr. Singh served as Joint Managing Director of Alkem Laboratories Limited since February 20, 2015 u...
CEO Compensation Analysis
Compensation vs Market: Sandeep's total compensation ($USD1.57M) is above average for companies of similar size in the Indian market ($USD765.90K).
Compensation vs Earnings: Sandeep's compensation has increased by more than 20% in the past year.
Experienced Management: 539523's management team is seasoned and experienced (5.9 years average tenure).
Experienced Board: 539523's board of directors are considered experienced (6.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 539523 insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Alkem Laboratories Limited's employee growth, exchange listings and data sources
- Name: Alkem Laboratories Limited
- Ticker: 539523
- Exchange: BSE
- Founded: 1973
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹413.007b
- Shares outstanding: 119.57m
- Website: https://www.alkemlabs.com
Number of Employees
- Alkem Laboratories Limited
- Devashish Building
- Alkem House
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/26 12:03|
|End of Day Share Price||2022/01/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.